Today, there is no cure for ALS although the pace of drug research has accelerated greatly since the Ice Bucket Challenge.
For many years, Riluzole was the only drug shown to slow progressions of ALS slightly. Recently, Edaravone became the second agent approved in the management of patients with ALS. The mechanism of either drug is not well known. Riluzole is thought to reduce damage to motor neurons through an inhibitory effect on glutamate release, while Edaravone is thought to act as a neuroprotective agent that prevents oxidative stress damage as a free radical scavenger. With the lack of treatment options, it is imperative for healthcare professionals to understand the nuances of using these 2 agents to optimize therapy and quality of life for patients with ALS.
There are treatments, strategies and equipment to make you as comfortable as possible and aid in breathing, mobility, and communication.
Your multi-disciplinary team at the ALS Clinic will be of great assistance helping you make decisions about interventions and equipment.
New Brunswick – The Stan Cassidy Centre for Rehabilitation
Tel: 506-447-4082
Nova Scotia – Capital District Health Authority – Queen Elizabeth II Health Sciences Centre
Tel: 902-473-5565
In ALS, the nerve cells that control the movement of your muscles gradually die, so your muscles progressively weaken and begin to waste away. ALS is recognized as having multiple interacting causes.
Researchers are studying several possible causes of ALS, including:
Source – mayoclinic.org